Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles, such as increased on-target off-tumor toxicities,...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/2/287 |
id |
doaj-89b2e23257904dc59552d9def0a249ce |
---|---|
record_format |
Article |
spelling |
doaj-89b2e23257904dc59552d9def0a249ce2021-01-15T00:02:33ZengMDPI AGCancers2072-66942021-01-011328728710.3390/cancers13020287Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid TumorsJim Middelburg0Kristel Kemper1Patrick Engelberts2Aran F. Labrijn3Janine Schuurman4Thorbald van Hall5Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsGenmab, 3584 CT Utrecht, The NetherlandsGenmab, 3584 CT Utrecht, The NetherlandsGenmab, 3584 CT Utrecht, The NetherlandsGenmab, 3584 CT Utrecht, The NetherlandsDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsImmunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles, such as increased on-target off-tumor toxicities, sparse T-cell infiltration and impaired T-cell quality due to the presence of an immunosuppressive tumor microenvironment, which affect the safety and limit efficacy of CD3-bispecific antibody therapy. In this review, we provide a brief status update of the CD3-bispecific antibody therapy field and identify intrinsic hurdles in solid cancers. Furthermore, we describe potential combinatorial approaches to overcome these challenges in order to generate selective and more effective responses.https://www.mdpi.com/2072-6694/13/2/287antibody therapyimmuno-oncologyCD3-bispecific antibodyT-cell engagersolid tumorson-target off-tumor toxicity |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jim Middelburg Kristel Kemper Patrick Engelberts Aran F. Labrijn Janine Schuurman Thorbald van Hall |
spellingShingle |
Jim Middelburg Kristel Kemper Patrick Engelberts Aran F. Labrijn Janine Schuurman Thorbald van Hall Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors Cancers antibody therapy immuno-oncology CD3-bispecific antibody T-cell engager solid tumors on-target off-tumor toxicity |
author_facet |
Jim Middelburg Kristel Kemper Patrick Engelberts Aran F. Labrijn Janine Schuurman Thorbald van Hall |
author_sort |
Jim Middelburg |
title |
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors |
title_short |
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors |
title_full |
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors |
title_fullStr |
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors |
title_full_unstemmed |
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors |
title_sort |
overcoming challenges for cd3-bispecific antibody therapy in solid tumors |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-01-01 |
description |
Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles, such as increased on-target off-tumor toxicities, sparse T-cell infiltration and impaired T-cell quality due to the presence of an immunosuppressive tumor microenvironment, which affect the safety and limit efficacy of CD3-bispecific antibody therapy. In this review, we provide a brief status update of the CD3-bispecific antibody therapy field and identify intrinsic hurdles in solid cancers. Furthermore, we describe potential combinatorial approaches to overcome these challenges in order to generate selective and more effective responses. |
topic |
antibody therapy immuno-oncology CD3-bispecific antibody T-cell engager solid tumors on-target off-tumor toxicity |
url |
https://www.mdpi.com/2072-6694/13/2/287 |
work_keys_str_mv |
AT jimmiddelburg overcomingchallengesforcd3bispecificantibodytherapyinsolidtumors AT kristelkemper overcomingchallengesforcd3bispecificantibodytherapyinsolidtumors AT patrickengelberts overcomingchallengesforcd3bispecificantibodytherapyinsolidtumors AT aranflabrijn overcomingchallengesforcd3bispecificantibodytherapyinsolidtumors AT janineschuurman overcomingchallengesforcd3bispecificantibodytherapyinsolidtumors AT thorbaldvanhall overcomingchallengesforcd3bispecificantibodytherapyinsolidtumors |
_version_ |
1724337855163006976 |